Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Interventional, Observational Phase IV Study to Evaluate Safety of Rituximab (Mabthera®) in Combination With Chemotherapy in Patients Treated With CD20+ Β Chronic Lymphocytic Leukemia

NCT01609023 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01609023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01609023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Interventional, Observational Phase IV Study to Evaluate Safety of Rituximab (Mabthera®) in Combination With Chemotherapy in Patients Treated With CD20+ Β Chronic Lymphocytic Leukemia
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
April 30, 2012
Completion date
November 30, 2015
Enrollment
67 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

lymphocytic leukemia, chronic